<DOC>
	<DOCNO>NCT00506935</DOCNO>
	<brief_summary>The purpose study find GVG reduce drug use determine safety effect GVG use together methamphetamine . This study involve stay hospital 21 day . Participants receive either placebo GVG , limited amount methamphetamine inject study day . This study enroll people use methamphetamine . Participants compensate .</brief_summary>
	<brief_title>Assessment GVG Treatment Methamphetamine Dependence</brief_title>
	<detailed_description />
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Vigabatrin</mesh_term>
	<criteria>1 . Be Englishspeaking volunteer seek treatment time study ; 2 . Be 1855 year age ; 3 . Meet DSMIV TR criterion MA abuse dependence ; 4 . Have selfreported history use MA smoke IV route , least 2 year . 5 . Have vital sign follow : resting pulse 50 90 bpm , blood pressure 85150mm Hg systolic 4590mm Hg diastolic ; criterion must meet within 2 day admission . 6 . Have hematology chemistry laboratory test within normal ( +/ 10 % ) limit follow exception : ) liver function test ( total bilirubin , ALT , AST , alkaline phosphatase ) &lt; 3 x upper limit normal , b ) kidney function test ( creatinine BUN ) &lt; 2 x upper limit normal ; 7 . Have baseline ECG demonstrate normal sinus rhythm , normal conduction , clinically significant arrhythmia ; 8 . Be able fully cooperate visual field test point valid test obtain screening/baseline . 9 . In judgment study ophthalmologist , visual field within normal limit age screening/baseline measurement ; 10 . Have acceptable ERG result initiation treatment GVG ( judgment Drs . Nusinowitz Newton , ophthalmologic consultation need ) , include value 30 Hz Flicker ab amplitude measure screening/baseline electroretinogram evaluation 52 Î¼V ; 11 . Have medical history brief physical examination demonstrate clinically significant contraindication study participation , judgment admit physician principal investigator . 1 . Have history evidence suggestive seizure disorder brain injury ; 2 . Have previous medically adverse reaction MA , include loss consciousness , chest pain , epileptic seizure ; 3 . Have neurological psychiatric disorder , : psychosis , bipolar illness major depression assess MINI ; organic brain disease dementia assess clinical interview ; history psychiatric disorder would require ongoing treatment would make study compliance difficult ; history suicide attempt within past three month assess MINI and/or current suicidal ideation/plan assess MINI ; 4 . Have evidence clinically significant heart disease hypertension , determine PI ; 5 . Have family history firstdegree relatives early cardiovascular morbidity mortality , determine PI ; 6 . Have ophthalmologic disorder ( e.g. , glaucoma , cataract , optic nerve disease , fixation problem , etc . ) , judgment study ophthalmologist , would : make difficult obtain valid ophthalmologic perimetry , electroretinography ( ERG ) assessment , increase risk visual side effect associate VGB . 7 . Have evidence untreated unstable medical illness include : neuroendocrine , autoimmune , renal , hepatic , active infectious disease ; 8 . Have HIV currently symptomatic , diagnosis AIDS , receive antiretroviral medication ; 9 . Be pregnant nursing . Other female must either unable conceive ( i.e. , surgically sterilize , sterile , postmenopausal ) use reliable form contraception ( e.g. , abstinence , birth control pill , intrauterine device , condom , spermicide ) . All female must provide negative pregnancy urine test study entry , upon hospital admission , end study participation ; 10 . Have history asthma , chronic cough wheezing , respiratory illness ; 11 . Currently use alpha beta agonist , theophylline , sympathomimetics ; 12 . Have illness , condition , use medication , opinion PI and/or admit physician would preclude safe and/or successful completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>methamphetamine</keyword>
	<keyword>GVG</keyword>
	<keyword>vigabatrin</keyword>
	<keyword>stimulant</keyword>
</DOC>